Terms: = Gastric cancer AND PREX2, 6230420N16Rik, DEPDC2, 80243, ENSG00000046889, FLJ12987, DEP_2, P-REX2 AND Treatment
3 results:
1. The predicting role of circulating tumor DNA landscape in gastric cancer patients treated with immune checkpoint inhibitors.
Jin Y; Chen DL; Wang F; Yang CP; Chen XX; You JQ; Huang JS; Shao Y; Zhu DQ; Ouyang YM; Luo HY; Wang ZQ; Wang FH; Li YH; Xu RH; Zhang DS
Mol Cancer; 2020 Oct; 19(1):154. PubMed ID: 33126883
[TBL] [Abstract] [Full Text] [Related]
2. Neoantigens Derived from Recurrently Mutated Genes as Potential Immunotherapy Targets for gastric cancer.
Zhou J; Zhao W; Wu J; Lu J; Ding Y; Wu S; Wang H; Ding D; Mo F; Zhou Z; Teng L; Chen S
Biomed Res Int; 2019; 2019():8103142. PubMed ID: 31312661
[TBL] [Abstract] [Full Text] [Related]
3. miR-338-3p suppresses gastric cancer progression through a PTEN-AKT axis by targeting p-rex2a.
Guo B; Liu L; Yao J; Ma R; Chang D; Li Z; Song T; Huang C
Mol Cancer Res; 2014 Mar; 12(3):313-21. PubMed ID: 24375644
[TBL] [Abstract] [Full Text] [Related]
